MRI-Guided Adaptive Radiotherapy for Limited Peritoneal Metastases (MARACAS Trial).
Starting soon · Phase 2
Conditions studied: Peritoneal Carcinomatosis, Oligometastatic Disease, Peritoneal Metastases
In brief
This prospective phase II study evaluates the efficacy and safety of MRI-guided stereotactic body radiotherapy (MRIgSBRT) in patients with oligometastatic peritoneal carcinomatosis from gastrointestinal or gynecological tumors. Eligible patients with up to 5 MRI-visible peritoneal lesions and PCI ≤20 will be treated with MRIgSBRT using a hybrid MRI-linear accelerator with online adaptive planning and real-time tumor tracking. The primary endpoint is radiologic response rate according to RECIST 1.1 criteria. Secondary endpoints include overall survival, progression-free survival, local control, chemotherapy-free survival, and treatment-related toxicity. The study aims to assess MRIgSBRT as a safe and non-invasive treatment option for selected patients with limited peritoneal metastatic disease.
Key facts
- Study ID
- NCT07593261
- Run by
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
- People needed
- 34
- Starts
- 2026-07-01
- Expected to finish
- 2032-07-01
- Last updated by the study team
- 2026-05-18
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Age ≥18 years
- ECOG performance status 0-2
- Life expectancy ≥6 months
- Up to 5 MRI-visible peritoneal nodules
- PCI ≤20
- No prior radiotherapy in the same abdominal region within 6 months
- Signed informed consent
- History of prior CRS and/or HIPEC
You may not qualify if…
- Diffuse peritoneal carcinomatosis
- Psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule (those conditions should be discussed with the patient before registration in the trial)
- Significant comorbidities (such as: severe cardiac or coagulative disease, moderate or severe
- restrictive/obsiructive lung deficit, severe cognitive impairment, moderate and severe renal and hepatic impairment.
- Pregnancy or breastfeeding
- MRI contraindications (e.g., pacemaker, severe claustrophobia)
Where it is running
- Gemelli ART (Advanced Radiation Therapy)-Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Roma, Italy
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.